Press coverage about Ocular Therapeutix (NASDAQ:OCUL) has been trending somewhat positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ocular Therapeutix earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.7246293899441 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Ocular Therapeutix (NASDAQ:OCUL) Earning Somewhat Positive News Coverage, Analysis Finds (overnewsmagazine.com)
- How Analysts Rated Ocular Therapeutix Inc (NASDAQ:OCUL) Last Week? (campdesrecrues.com)
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL (finance.yahoo.com)
- APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm (finance.yahoo.com)
- Edited Transcript of OCUL earnings conference call or presentation 8-Aug-17 9:00pm GMT (finance.yahoo.com)
OCUL has been the subject of several research analyst reports. Zacks Investment Research raised Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Tuesday, May 16th. Morgan Stanley downgraded Ocular Therapeutix from an “overweight” rating to an “equal weight” rating and set a $16.00 price objective for the company. in a research note on Friday, June 23rd. HC Wainwright set a $10.00 price target on Ocular Therapeutix and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. BTIG Research downgraded Ocular Therapeutix from a “buy” rating to a “neutral” rating in a research note on Monday, May 15th. Finally, Cantor Fitzgerald cut their price target on Ocular Therapeutix from $35.00 to $21.00 and set an “overweight” rating for the company in a research note on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $22.14.
Ocular Therapeutix (OCUL) traded up 2.94% during midday trading on Friday, hitting $5.95. The stock had a trading volume of 337,824 shares. The stock has a 50-day moving average of $7.24 and a 200-day moving average of $8.63. The firm’s market cap is $172.88 million. Ocular Therapeutix has a 52 week low of $4.82 and a 52 week high of $11.91.
Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by $0.05. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.51 million. Ocular Therapeutix had a negative net margin of 3,005.52% and a negative return on equity of 101.03%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.46) earnings per share. Analysts forecast that Ocular Therapeutix will post ($2.21) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first published by Rincon Hill News and is owned by of Rincon Hill News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://rinconhillneighbors.org/2017/08/12/ocular-therapeutix-ocul-given-daily-media-impact-rating-of-0-05-updated.html.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with our FREE daily email newsletter.